Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51

被引：33

作者：

Schuller, Elisabeth ^{[2
]}

Klade, Christoph S. ^{[2
]}

Heinz, Franz X. ^{[4
]}

Kollaritsch, Herwig ^{[1
]}

Rendi-Wagner, Pamela ^{[1
]}

Jilma, Bernd ^{[3
]}

Tauber, Erich ^{[2
]}

机构：

[1] Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Specif Prophylaxis & Trop Med, A-1095 Vienna, Austria

[2] Intercell AG, A-1030 Vienna, Austria

[3] Med Univ Vienna, A-1090 Vienna, Austria

[4] Med Univ Vienna, Inst Virol, A-1095 Vienna, Austria

来源：

VACCINE | 2008年 / 26卷 / 48期

关键词：

Flavivirus; IC51; Vaccination; TBEV; JEV; Neutralising antibody; ELISA;

D O I：

10.1016/j.vaccine.2008.08.056

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in Asia with a case fatality rate up to 35% and long-term sequelae up to 75%. This active-controlled, randomized, multi-centre, observer-blind, phase III trial investigated the neutralising antibody response to the new Japanese encephalitis (JE) vaccine IC51 in subjects with (N=81) and without (N=339) pre-existing tick-borne encephalitis (TBE) vaccine induced antibodies as determined by TBE enzyme-linked immunosorbent assay IgG (ELISA). Neutralising antibody response was statistically superior in TBE ELISA-positive subjects compared to TBE ELISA-negative Subjects after the first (p < 0.0001) but not after the second vaccination with IC51. Thus, pre-existing vaccine-induced THE immunity enhances the neutralising JEV-specific antibody response after a single IC51 vaccination. (C) 2008 Published by Elsevier Ltd.

引用

页码：6151 / 6156

页数：6

共 37 条

[1]

[Anonymous], 1988, The arboviruses: epidemiology and ecology, vol

[2]

Bharati Kaushik, 2006, Expert Rev Anti Infect Ther, V4, P313, DOI 10.1586/14787210.4.2.313

[3] After a tick bite in a tick-borne encephalitis virus endemic area:: Current positions about post-exposure treatment [J].

Broekera, Michael ;

Kollaritsch, Herwig .

VACCINE, 2008, 26 (07) :863-868

[4] Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes [J].

Crill, WD ;

Chang, GJJ .

JOURNAL OF VIROLOGY, 2004, 78 (24) :13975-13986

[5] JAPANESE ENCEPHALITIS-VIRUS LIVE-ATTENUATED VACCINE, CHINESE STRAIN SA14-14-2 - ADAPTATION TO PRIMARY CANINE KIDNEY-CELL CULTURES AND PREPARATION OF A VACCINE FOR HUMAN USE [J].

ECKELS, KH ;

YONGXIN, Y ;

DUBOIS, DR ;

MARCHETTE, NJ ;

TRENT, DW ;

JOHNSON, AJ .

VACCINE, 1988, 6 (06) :513-518

[6] The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens [J].

Ferguson, N ;

Anderson, R ;

Gupta, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) :790-794

[7]

HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268

[8] PASSIVE-IMMUNITY FOR ARBOVIRUS INFECTION .1. ARTIFICIALLY INDUCED PROPHYLAXIS IN MAN AND MOUSE FOR JAPANESE (B) ENCEPHALITIS [J].

HAMMON, WMD ;

SATHER, GE .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1973, 22 (04) :524-534

[9] Field effectiveness of vaccination against tick-borne encephalitis [J].

Heinz, Franz X. ;

Holzmann, Heidemarie ;

Essl, Astrid ;

Kundi, Michael .

VACCINE, 2007, 25 (43) :7559-7567

[10]

HOFMANN H, 1983, ZBL BAKT-INT J MED M, V255, P448

← 1 2 3 4 →